Jin Medical International Ltd. current report, Q4 FY2023

Full document

Jin Medical International Ltd. — Form 6-K Summary

Business Context and Reporting Period

This Form 6-K, dated December 20, 2023, covers the month of December 2023. Jin Medical International Ltd. is a foreign private issuer headquartered in Changzhou, Jiangsu Province, China, and files annual reports on Form 20-F.

Material Listing and Regulatory Developments

  • On September 25, 2023, Nasdaq notified the Company that it was not in compliance with Listing Rule 5550(a)(3), which requires at least 300 public holders for continued listing.
  • On December 18, 2023, Nasdaq determined that the Company had not provided a sufficiently detailed compliance plan and that its initial public offering allocation did not satisfy the 300 round-lot holder requirement for initial listing on the Nasdaq Capital Market.
  • Nasdaq initiated procedures to delist the Company’s ordinary shares. Unless appealed, trading would be suspended at the opening of business on December 28, 2023, and Nasdaq would file a Form 25-NSE with the SEC.
  • The Company stated that it would request a hearing before the Nasdaq Hearings Panel. The request would stay the suspension and Form 25-NSE filing pending the Panel’s decision.

Financial Metrics and Liquidity

The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other operating or financial metrics.

Outlook, Risks, and Unusual Items

  • The Company’s continued Nasdaq listing is uncertain, and there can be no assurance that its appeal will be successful.
  • The potential suspension and delisting could adversely affect trading liquidity, investor access, and the market for the Company’s ordinary shares.
  • The delisting process does not relieve the Company of its obligation to file periodic and other reports with the SEC under applicable federal securities laws.

Important Facts for Investors to Verify

  • Whether the Company timely requested a Nasdaq Hearings Panel hearing.
  • The Panel’s decision and whether the suspension or Form 25-NSE filing was stayed or ultimately completed.
  • The Company’s subsequent trading venue and the liquidity of its ordinary shares.
  • Any later SEC filings describing the listing status, shareholder distribution, or related legal and financial consequences.